ClinicalTrials.gg
TerminatedNCT02654587ATALANTE-1Updated Feb 2, 2024Results posted

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Phase 3 interventional study of OSE2101 and Docetaxel in Non Small Cell Lung Cancer, sponsored by OSE Immunotherapeutics. Terminated at 78 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by OSE Immunotherapeutics · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
due to COVID-19

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France — 170 open to participants now, 327 under way, 105 of them phase 3. Carcinoma, Non-Small-Cell Lung · France.

Enrollment
358th of 762
219 · median 190
Started
2016
with 37 others
Phase 3
236 of 875
42 open now
Registered
318th of 875
by date

Among the 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France, this one is the 358th largest by enrollment of the 762 interventional ones that give a count, is one of 38 that started in 2016, is one of 236 in phase 3, and was the 318th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

170 of the 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France, or all of them as a file.
02

Study summary

The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune checkpoint inhibitor given in first or second-line treatment.

The main questions were to compare the survival, the tolerance to treatment and the quality of life of patients between the two arms of treatment (OSE2101 versus standard chemotherapy)

Read the detailed description

The study was a two-step randomized (2:1) study. Patients were stratified by histology (non-squamous versus squamous), best response to first-line treatment [complete response or partial response versus stable disease or progressive disease] and line of treatment with prior ICI (first-line ICI when combined with platinum-based chemotherapy versus second-line ICI when administered as sequential treatment). Primary endpoint was overall survival (OS). Interim OS futility analysis was planned as per Fleming design. In April 2020 at the time of the interim analysis, a decision was taken to early stop the accrual due to COVID-19 after 219 out of 363 patients were randomized. It led to a decrease of the study power from 80% to 62%. At the time of the interim analysis, a subgroup of patients was identified from stratification factor based on a clinical and biological rationale: those who received ICI second line and having received at least 12 weeks ICI. This subgroup was defined as ICI secondary resistance. The final analysis was carried out in the subgroup of patients with ICI secondary resistance and in all patients (ICI primary and secondary resistance).

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Advanced Non-Small-Cell Lung Cancer
  • Therapeutic Cancer Vaccine
  • Resistance to Immunotherapy
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated
  2. Willingness and ability to comply with the clinical study procedures.
  3. Female or male, 18 years of age or older
  4. or cytologically proven diagnosis of Non-Small Cell Lung Cancer (NSCLC) that is locally advanced (stage III) unsuitable for radiotherapy or (stage IV) according to the 8th edition of tumor, node, metastasis (TNM) in Lung Cancer
  5. Subjects with disease recurrence or progression after and platinum-based chemotherapy:

    i) either chemotherapy followed by 2nd line immune checkpoint inhibitor, or ii) 1st line combination of immune checkpoint inhibitor and chemotherapy Patients with progression during or within 12 months after the end of immune checkpoint inhibitor given as sequential or concomitant platinum-based chemotherapy ± radiation for locally advanced disease (stage III) were eligible

  6. Subjects with measurable or non- according to 1.1
  7. Subjects must express HLA-A2 phenotype (central test in blood)
  8. Subjects must be considered suitable for chemotherapy with single-agent pemetrexed or single-agent docetaxel
  9. Subjects with were eligible if treated (whole brain radiotherapy, stereotaxic radiotherapy, surgery) at least 3 weeks prior to initiation of study treatment and have no symptoms related to brain metastases for at least 2 weeks before initiation of study treatment and are not taking any forbidden medications
  10. Any prior chemotherapy, immunotherapy, hormonal therapy, radiation therapy or surgeries must have been completed at least 3 weeks prior to initiation of study treatment.
  11. Any toxicity from prior therapy must have recovered to ≤ Grade 1 (except alopecia)
  12. (ECOG) performance status 0-1
  13. Adequate organ function as defined by all the following criteria:

    • Albuminemia > 25g/L
    • Serum (AST) and serum alanine transaminase (ALT) ≤ 1.5 x (ULN) with alkaline phosphatase ≤ 2.5 x ULN, or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to liver metastases
    • Total serum ≤ 1.5 x ULN
    • (ANC) ≥ 1500/L
    • ≥ 100000/L
    • ≥ 9.0 g/dL (in the absence of transfusion within 2 weeks before randomization)
    • (based on modified Cockcroft-Gault formula) ≥ 45 ml/min.

Exclusion criteria

Exclusion Criteria:

  1. Small-cell lung cancer/mixed NSCLC with small cell component or other neuroendocrine lung cancers (typical and atypical carcinoids, large-cell neuroendocrine carcinomas)
  2. Patients with squamous cell carcinoma histology, and who had docetaxel as part of his prior chemotherapy
  3. Current or previous treatment with therapy in another therapeutic clinical trial (interrupted less than 4 weeks before study treatment initiation)
  4. Patients whose tumor harbors EGFR gene mutation that sensitizes tumors to Tyrosine-Kinase Inhibitor (TKI) (EGFR exon 18-21) or Anaplastic Lymphoma Kinase (ALK) rearrangement
  5. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be scheduled to continue concomitantly to the study)
  6. Spinal cord compression (unless treated with the patient attaining good pain control and stable or recovered neurologic function), carcinomatous meningitis, or
  7. Patients with squamous cell histology or non-squamous cell histology previously treated by pemetrexed with a for docetaxel with grade ≥ 2 neuropathy or reaction to medications formulated with polysorbate 80 (Tween 80)
  8. Patients with a condition requiring systemic treatment with either or other medications
  9. Treatment with corticosteroids in the last 3-week period before inclusion, except for topical, ocular, intra-articular, intranasal, and inhaled corticosteroids with minimal systemic absorption (e.g. with a dose ≤ 500 microgram beclomethasone equivalent for inhaled steroids), or steroid doses ≤ 10 mg daily prednisone equivalent which are permitted
  10. A recognized immunodeficiency disease including (HIV) infection (and other cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary, congenital or acquired immunodeficiencies)
  11. Patients with auto-immune disease, with the exception of type I diabetes or treated hypothyroidism
  12. Patients with interstitial lung disease
  13. Patients with active B or C hepatitis
  14. Other : patients will not be eligible if they have evidence of other active invasive cancer(s) (other than NSCLC) within 5 years prior to screening (except appropriately treated non-melanoma skin cancer or localized cervical cancer, or other local tumors considered cured (e.g.localized and presumed cured prostate cancer)
  15. Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study
  16. Female patients must be surgically sterile or be , or must agree to use effective during the period of the trial and for at least 90 days after completion of treatment
  17. Male patients sexually active with a woman of must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator
  18. Breastfeeding women
  19. Women with a positive pregnancy test.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    OSE2101

    OSE2101 was administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit of OSE2101. OSE2101 dose was 5 mg of peptides (0.5 mg for each peptide).

    Biological: OSE2101

  • Active comparator
    Docetaxel or Pemetrexed

    Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle. Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle. Docetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal.

    Drug: Docetaxel · Drug: Pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS defined as the time from randomisation to death from any cause in patients with ICI secondary resistance

    Time frame: Approx. 24 months

Secondary outcomes

  1. Post-Progression Survival

    Post-progression survival was defined as the time from the earliest date of progression according to RECIST 1.1 until death in patients with ICI secondary resistance

    Time frame: approximately 24 months

  2. Time to Worsening ECOG PS

    Time to Worsening ECOG PS was defined as the time from randomization to the earliest date when ECOG PS was \>1 in patients with ICI secondary resistance. Time to worsening ECPG PS was summarized by treatment arm using the Kaplan-Meier method. The median event time for each treatment arm and the corresponding 2-sided 95% confidence interval were provided. By protocol, ECOG PS was not collected when a patient permanenetly discontinued the study treatment. Patients without ECOG PS worsening were censored at the last time when an ECOG value was recorded.

    Time frame: Approx. 24 months

  3. Mean Changes in Functional Subscales of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance

    Mean change from baseline to treatment discontinuation in Quality of Life (QoL) score of the following functional subscales analyzed separately: global health status, physical, role, cognitive, emotional and social functioning. Each score range from 0 to 100 after normalisation. Highest scores correspond to a better quality of life. The mean score change was assessed using a mixed-effects model for repeated measures analysis with the patient as the random effect, treatment, visit and treatment-by-visit interaction as explanatory variables and baseline score as covariates. If the mean score change is negative, it means a deterioration of QoL. If the mean score change is positive or 0, it means an improvement or stability of QoL

    Time frame: Approx. 24 months

  4. Mean Changes in Symptoms Subscales of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance

    Mean change from baseline to treatment discontinuation in Quality of Life (QoL) score of the following symptoms subscales analyzed separately: Fatigue, Constipation, Dyspnea, Nausea and Vomiting, Pain, Insomnia, Appetite loss, Diarrhea, Financial Difficulties. Each score range from 0 to 100 after normalisation. Lowest scores correspond to a better QoL. The mean score change was assessed using a mixed-effects model for repeated measures analysis with the patient as the random effect, treatment, visit and treatment-by-visit interaction as explanatory variables and baseline score as covariates. If the mean score change is negative, it means a deterioration of QoL. If the mean score change is positive or 0, it means an improvement or stability of QoL.

    Time frame: Approx. 24 months

  5. Mean Changes in Symptoms Subscales of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Lung Cancer (QLQ-LC13) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance

    Mean change from baseline to treatment discontinuation in Quality of Life (QoL) score of the following symptoms subscales analyzed separately: Alopecia, Peripheral Neuropathy, Sore mouth, Dysphagia, Dyspnea, Pain in arm or shoulder, Pain in chest, Pain in other parts, Hemoptysis, Coughing. Each score range from 0 to 100 after normalisation. Lowest scores correspond to a better QoL. The mean score change was assessed using a mixed-effects model for repeated measures analysis with the patient as the random effect, treatment, visit and treatment-by-visit interaction as explanatory variables and baseline score as covariates. If the mean score change is negative, it means a deterioration of QoL. If the mean score change is positive or 0, it means an improvement or stability of QoL.

    Time frame: Approx. 24 months

  6. Disease Control Rate (DCR) at 6 Months

    DCR at 6 months defined as the number of patients with Complete Response (CR), Partial Response (PR) or Stable Disease (SD) assessed by investigator per "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions based on CT scan in patients with ICI secondary resistance. Complete Response (CR) defined as disappearance of all target lesions; Partial Response (PR) as \>=30% decrease in the sum of the longest diameter of target lesions; Stable disease (SD) defined as neither sufficient shrinkage (compared to baseline) to qualify for CR or PR nor sufficient increase (taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest) to qualify for progressive disease (PD) (e.g. decrease of the sum of the longest diameters of target lesions \<30% or increase up to 20%)

    Time frame: Approx. 6 months

  7. Progression Free Survival (PFS) in Patients With ICI Secondary Resistance

    PFS was defined as the time from randomization to the earliest date of progression assessed by investigator per "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions based on CT scan in patients with ICI secondary resistance. Progressive disease (PD) defined as increase of target lesions \>=20% taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest)

    Time frame: Approx. 24 months

Other outcomes

  1. Objective Response Rate (ORR) in ICI Secondary Resistance

    Objective Response rate (OOR) was defined as number of patients with Complete Response (CR) + Partial Response (PR) assessed by investigator per "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions based on CT scan in patients with ICI secondary resistance. Complete Response (CR) defined as disappearance of all target lesions; Partial Response (PR) as \>=30% decrease in the sum of the longest diameter of target lesions. Investigator-assessed ORR was an exploratory endpoint as not relevant as primary, nor secondary endpoints to evaluate a cancer vaccine.

    Time frame: Approx. 24 months

  2. Percentage of Patients With Objective Response at 6 Months in ICI Secondary Resistance

    Duration of Objective Response (OOR) was defined as number of patients with Complete Response (CR) or Partial Response (PR) at 6 months assessed by investigator per "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions based on CT scan in patients with ICI secondary resistance. Complete Response (CR) defined as disappearance of all target lesions; Partial Response (PR) as \>=30% decrease in the sum of the longest diameter of target lesions

    Time frame: Approx. 6 months

  3. Time to Next Lung Cancer Therapy in ICI Secondary Resistance

    Time to next lung cancer therapy was defined as the time from randomisation to the date of initiation of the first lung cancer therapy during the survival follow-up form

    Time frame: Approx. 24 months

07

Results

Posted Feb 2, 2024
Limitations and caveats
In April 2020 at time of planned interim analysis, decision was taken to prematurely stop the accrual due to COVID-19. Early termination led to small numbers of subject analyzed. The statistical plan was revised to propose the primary efficacy analysis in subgroup of patients with ICI secondary resistance (defined as progression after ICI second line \>= to 12 weeks from stratification criteria based on biological and clinical rationale).

Participant flow

From Feb 2016 to Apr 2020, patients with advanced NSCLC were recruited in clinics or hospitals specialized in oncology in Europe, US and Israel to prescreen potential patients for HLA-A2 typing (by central lab). Only HLA-A2 positive patients who fulfilled all eligibility criteria were randomized. A total of 219 patients with ICI resistance were randomized, including 118 patients with ICI secondary resistance (disease progression after ICI \>= 12 weeks - primary population for efficacy analysis)

Participant flow — Overall Study
MilestoneOSE2101Docetaxel or Pemetrexed
Started13980
Completed11665
Not completed2315
Withdrew: Patient alive at end of study228
Withdrew: Withdrawal by subject17

Outcome measures

PrimaryOverall Survival (OS)

OS defined as the time from randomisation to death from any cause in patients with ICI secondary resistance

Time frame:
Approx. 24 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsOSE2101Docetaxel or Pemetrexed
Overall Survival (OS)11.1 (8.6 to 13.5)7.5 (4.7 to 10.3)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · t-test, 2 sided · p = <0.05 (OS in patients with ICI secondary resistance) · Hazard ratio (hr): 0.59 · 95% CI 0.38 to 0.91p=0.017
  • OSE2101 vs Docetaxel or Pemetrexed · t-test, 2 sided · p = 0.36 · Hazard ratio (hr): 0.86 · 95% CI 0.62 to 1.19
SecondaryPost-Progression Survival

Post-progression survival was defined as the time from the earliest date of progression according to RECIST 1.1 until death in patients with ICI secondary resistance

Time frame:
approximately 24 months
Reported as:
Median · months
Post-Progression Survival
monthsOSE2101Docetaxel or Pemetrexed
Post-Progression Survival7.7 (5.6 to 9.7)4.6 (3.1 to 5.8)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · t-test, 2 sided · p = 0.004 · Hazard ratio (hr): 0.46 · 95% CI 0.27 to 0.79
  • OSE2101 vs Docetaxel or Pemetrexed · t-test, 2 sided · p = 0.0035 · Hazard ratio (hr): 0.57 · 95% CI 0.39 to 0.83
SecondaryTime to Worsening ECOG PS

Time to Worsening ECOG PS was defined as the time from randomization to the earliest date when ECOG PS was \>1 in patients with ICI secondary resistance. Time to worsening ECPG PS was summarized by treatment arm using the Kaplan-Meier method. The median event time for each treatment arm and the corresponding 2-sided 95% confidence interval were provided. By protocol, ECOG PS was not collected when a patient permanenetly discontinued the study treatment. Patients without ECOG PS worsening were censored at the last time when an ECOG value was recorded.

Time frame:
Approx. 24 months
Reported as:
Median · months
Time to Worsening ECOG PS
monthsOSE2101Docetaxel or Pemetrexed
Time to Worsening ECOG PS9.0 (6.3 to 9.9)3.3 (2.3 to 6.7)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · t-test, 2 sided · p = 0.006 · Hazard ratio (hr): 0.43 · 95% CI 0.23 to 0.80
  • OSE2101 vs Docetaxel or Pemetrexed · t-test, 2 sided · p = 0.02 · Hazard ratio (hr): 0.57 · 95% CI 0.35 to 0.92
SecondaryMean Changes in Functional Subscales of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance

Mean change from baseline to treatment discontinuation in Quality of Life (QoL) score of the following functional subscales analyzed separately: global health status, physical, role, cognitive, emotional and social functioning. Each score range from 0 to 100 after normalisation. Highest scores correspond to a better quality of life. The mean score change was assessed using a mixed-effects model for repeated measures analysis with the patient as the random effect, treatment, visit and treatment-by-visit interaction as explanatory variables and baseline score as covariates. If the mean score change is negative, it means a deterioration of QoL. If the mean score change is positive or 0, it means an improvement or stability of QoL

Time frame:
Approx. 24 months
Reported as:
Least squares mean · score on a scale
Mean Changes in Functional Subscales of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance
score on a scaleOSE2101Docetaxel or Pemetrexed
Global Health Status0.77 (-2.92 to 4.47)-6.19 (-11.83 to -0.55)
Physical functioning-2.74 (-6.21 to 0.73)-8.75 (-14.17 to -3.33)
Role functioning-5.09 (-10.60 to 0.43)-16.78 (-25.29 to -8.28)
Emotional functioning0.50 (-3.29 to 4.28)-2.75 (-8.63 to 3.12)
Cognitive functioning-3.20 (-7.18 to 0.78)-7.64 (-13.86 to -1.43)
Social funtioning-3.82 (-8.30 to 0.66)-10.43 (-17.23 to -3.64)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = <0.05 · P value: 0.045
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.07 · P value: 0.07
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = <0.05 · P value: 0.03
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.36 · P value: 0.36
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.24 · P value: 0.24
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.11 · P value: 0.11
SecondaryMean Changes in Symptoms Subscales of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance

Mean change from baseline to treatment discontinuation in Quality of Life (QoL) score of the following symptoms subscales analyzed separately: Fatigue, Constipation, Dyspnea, Nausea and Vomiting, Pain, Insomnia, Appetite loss, Diarrhea, Financial Difficulties. Each score range from 0 to 100 after normalisation. Lowest scores correspond to a better QoL. The mean score change was assessed using a mixed-effects model for repeated measures analysis with the patient as the random effect, treatment, visit and treatment-by-visit interaction as explanatory variables and baseline score as covariates. If the mean score change is negative, it means a deterioration of QoL. If the mean score change is positive or 0, it means an improvement or stability of QoL.

Time frame:
Approx. 24 months
Reported as:
Least squares mean · score on a scale
Mean Changes in Symptoms Subscales of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance
score on a scaleOSE2101Docetaxel or Pemetrexed
Fatigue4.47 (0.21 to 8.72)11.95 (5.44 to 18.46)
Constipation-5.57 (-9.50 to -1.64)7.84 (1.97 to 13.71)
Dyspnea3.99 (-1.26 to 9.24)2.77 (-5.24 to 10.77)
Nausea and Vomiting-1.49 (-3.83 to 0.84)1.21 (-2.37 to 4.80)
Pain4.23 (-0.73 to 9.19)0.71 (-7.01 to 8.43)
Insomnia0.42 (-4.25 to 5.08)-0.29 (-7.24 to 6.65)
Appetite loss0.08 (-4.79 to 4.94)-2.33 (-9.66 to 4.99)
Diarrhea-4.12 (-7.85 to -0.38)-3.85 (-9.33 to 2.16)
Financial difficulties2.22 (-2.15 to 6.59)5.82 (-0.82 to 12.45)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.06 · P value: 0.06
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.0003 · P value: 0.0003
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.80 · P value: 0.80
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.21 · P value: 0.21
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.45 · P value: 0.45
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.87 · P value: 0.87
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.59 · P value: 0.59
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.88 · P value: 0.88
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.37 · P value: 0.37
SecondaryMean Changes in Symptoms Subscales of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Lung Cancer (QLQ-LC13) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance

Mean change from baseline to treatment discontinuation in Quality of Life (QoL) score of the following symptoms subscales analyzed separately: Alopecia, Peripheral Neuropathy, Sore mouth, Dysphagia, Dyspnea, Pain in arm or shoulder, Pain in chest, Pain in other parts, Hemoptysis, Coughing. Each score range from 0 to 100 after normalisation. Lowest scores correspond to a better QoL. The mean score change was assessed using a mixed-effects model for repeated measures analysis with the patient as the random effect, treatment, visit and treatment-by-visit interaction as explanatory variables and baseline score as covariates. If the mean score change is negative, it means a deterioration of QoL. If the mean score change is positive or 0, it means an improvement or stability of QoL.

Time frame:
Approx. 24 months
Reported as:
Least squares mean · units on a scale
Mean Changes in Symptoms Subscales of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Lung Cancer (QLQ-LC13) From Baseline to Treatment Discontinuation in Patients With ICI Secondary Resistance
units on a scaleOSE2101Docetaxel or Pemetrexed
Alopecia0.44 (-4.74 to 5.63)25.83 (17.52 to 34.14)
Peripheral neuropathy2.65 (-2.33 to 7.63)13.23 (5.37 to 21.08)
Sore mouth0.82 (-2.27 to 3.91)8.52 (3.69 to 13.35)
Dysphagia0.44 (-2.49 to 3.37)7.41 (2.85 to 11.98)
Dyspnea4.99 (0.87 to 9.11)5.19 (-1.57 to 11.95)
Pain in arm or shoulder5.00 (0.60 to 9.39)1.16 (-5.70 to 8.02)
Pain in chest1.61 (-2.38 to 5.60)-1.37 (-7.61 to 4.86)
Pain in other parts8.17 (1.98 to 14.37)6.56 (-3.04 to 13.17)
Hemoptysis0.05 (-1.61 to 1.71)-1.84 (-4.44 to 0.75)
Coughing-3.62 (-8.85 to 1.61)-6.67 (-14.92 to 1.58)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = <0.0001 · P value: 0.0001
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.03 · P value: 0.03
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.01 · P value: 0.01
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.01 · P value: 0.01
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.35 · P value: 0.35
  • OSE2101 vs Docetaxel or Pemetrexed · Mantel Haenszel · p = 0.43 · P value: 0.43
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.78 · P value: 0.78
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.23 · P value: 0.23
  • OSE2101 vs Docetaxel or Pemetrexed · Mixed Models Analysis · p = 0.54 · P value: 0.54
SecondaryDisease Control Rate (DCR) at 6 Months

DCR at 6 months defined as the number of patients with Complete Response (CR), Partial Response (PR) or Stable Disease (SD) assessed by investigator per "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions based on CT scan in patients with ICI secondary resistance. Complete Response (CR) defined as disappearance of all target lesions; Partial Response (PR) as \>=30% decrease in the sum of the longest diameter of target lesions; Stable disease (SD) defined as neither sufficient shrinkage (compared to baseline) to qualify for CR or PR nor sufficient increase (taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest) to qualify for progressive disease (PD) (e.g. decrease of the sum of the longest diameters of target lesions \<30% or increase up to 20%)

Time frame:
Approx. 6 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) at 6 Months
percentage of participantsOSE2101Docetaxel or Pemetrexed
Disease Control Rate (DCR) at 6 Months24.7 (15.6 to 35.8)23.7 (11.4 to 40.2)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · Mantel Haenszel · p = 0.87 · Odds ratio (or): 1.09 · 95% CI 0.43 to 2.75
  • OSE2101 vs Docetaxel or Pemetrexed · Mantel Haenszel · p = 0.37 · Odds ratio (or): 0.73 · 95% CI 0.36 to 1.46
SecondaryProgression Free Survival (PFS) in Patients With ICI Secondary Resistance

PFS was defined as the time from randomization to the earliest date of progression assessed by investigator per "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions based on CT scan in patients with ICI secondary resistance. Progressive disease (PD) defined as increase of target lesions \>=20% taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest)

Time frame:
Approx. 24 months
Reported as:
Median · Months
Progression Free Survival (PFS) in Patients With ICI Secondary Resistance
MonthsOSE2101Docetaxel or Pemetrexed
Progression Free Survival (PFS) in Patients With ICI Secondary Resistance2.69 (1.61 to 2.79)2.99 (2.56 to 4.47)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · t-test, 2 sided · p = 0.29 · Hazard ratio (hr): 1.28 · 95% CI 0.82 to 2.0
  • OSE2101 vs Docetaxel or Pemetrexed · t-test, 2 sided · p = <0.05 · Hazard ratio (hr): 1.64 · 95% CI 1.18 to 2.28
Other pre-specifiedObjective Response Rate (ORR) in ICI Secondary Resistance

Objective Response rate (OOR) was defined as number of patients with Complete Response (CR) + Partial Response (PR) assessed by investigator per "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions based on CT scan in patients with ICI secondary resistance. Complete Response (CR) defined as disappearance of all target lesions; Partial Response (PR) as \>=30% decrease in the sum of the longest diameter of target lesions. Investigator-assessed ORR was an exploratory endpoint as not relevant as primary, nor secondary endpoints to evaluate a cancer vaccine.

Time frame:
Approx. 24 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) in ICI Secondary Resistance
percentage of participantsOSE2101Docetaxel or Pemetrexed
Objective Response Rate (ORR) in ICI Secondary Resistance7.7 (2.9 to 16.0)18.4 (7.7 to 34.3)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · Mantel Haenszel · p = 0.07 · Odds ratio (or): 0.33 · 95% CI 0.10 to 1.11
  • OSE2101 vs Docetaxel or Pemetrexed · Mantel Haenszel · p = 0.002 · Odds ratio (or): 0.22 · 95% CI 0.08 to 0.59
Other pre-specifiedPercentage of Patients With Objective Response at 6 Months in ICI Secondary Resistance

Duration of Objective Response (OOR) was defined as number of patients with Complete Response (CR) or Partial Response (PR) at 6 months assessed by investigator per "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions based on CT scan in patients with ICI secondary resistance. Complete Response (CR) defined as disappearance of all target lesions; Partial Response (PR) as \>=30% decrease in the sum of the longest diameter of target lesions

Time frame:
Approx. 6 months
Reported as:
Number · percentage of with objective response
Percentage of Patients With Objective Response at 6 Months in ICI Secondary Resistance
percentage of with objective responseOSE2101Docetaxel or Pemetrexed
Percentage of Patients With Objective Response at 6 Months in ICI Secondary Resistance33.3 (4.6 to 67.6)26.8 (1.3 to 67.0)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · Regression, Cox · p = 0.88 · Hazard ratio (hr): 1.14 · 95% CI 0.25 to 5.30
  • OSE2101 vs Docetaxel or Pemetrexed · Regression, Cox · p = 0.57 · Hazard ratio (hr): 1.41 · 95% CI 0.43 to 4.60
Other pre-specifiedTime to Next Lung Cancer Therapy in ICI Secondary Resistance

Time to next lung cancer therapy was defined as the time from randomisation to the date of initiation of the first lung cancer therapy during the survival follow-up form

Time frame:
Approx. 24 months
Reported as:
Median · months
Time to Next Lung Cancer Therapy in ICI Secondary Resistance
monthsOSE2101Docetaxel or Pemetrexed
Time to Next Lung Cancer Therapy in ICI Secondary Resistance5.4 (4.8 to 7.7)9.4 (6.3 to 14.1)
Statistical analysis
  • OSE2101 vs Docetaxel or Pemetrexed · Regression, Cox · p = 0.04 · Hazard ratio (hr): 1.85 · 95% CI 1.03 to 3.31
  • OSE2101 vs Docetaxel or Pemetrexed · Regression, Cox · p = 0.02 · Hazard ratio (hr): 1.59 · 95% CI 1.07 to 2.36
Post-hocOverall Survival Before and During the COVID-19 Period

Survival was assessed from date of randomisation to death in the pre COVID-19 pandemic (patients randomised before february 2019 and followed up to 12 months) and during COVID-19 pandemic (patients randomised after february 2019 and followed up to january 2021)

Time frame:
Approx. 24 months
Reported as:
Median · months
Overall Survival Before and During the COVID-19 Period
monthsPatients in Pre-COVID-19 PeriodPatients in the COVID-19 Period
Overall Survival Before and During the COVID-19 Period9.4 (8.0 to 12.2)8.1 (6.5 to 9.1)
Statistical analysis
  • Patients in Pre-COVID-19 Period vs Patients in the COVID-19 Period · t-test, 2 sided · p = <0.05 · Hazard ratio (hr): 1.36 · 95% CI 1.00 to 1.86

Adverse events

Collected over Adverse Events were collected in each patient from the date of informed consent' signature until 4 weeks after the last dose of study treatment, up to 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OSE2101116/139 (83.5%)47/139 (33.8%)125/139 (89.9%)
Docetaxel or Pemetrexed65/80 (81.3%)33/80 (41.3%)67/80 (83.8%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventOSE2101Docetaxel or Pemetrexed
General physical health deteriorationGeneral disorders4/1395/80
Cytokine release syndromeImmune system disorders6/1390/80
Febrile neutropeniaBlood and lymphatic system disorders0/1393/80
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1393/80
DiarrheaGastrointestinal disorders1/1392/80
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1392/80
VomitingGastrointestinal disorders0/1392/80
Respiratory tract infectionInfections and infestations2/1392/80
Acute kidney injuryRenal and urinary disorders0/1392/80
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1392/80
Most frequent other events
Showing 10 of 40
Most frequent other events
EventOSE2101Docetaxel or Pemetrexed
AstheniaGeneral disorders32/13932/80
DiarrheaGastrointestinal disorders12/13921/80
AlopeciaSkin and subcutaneous tissue disorders1/13921/80
Decreased appetiteMetabolism and nutrition disorders28/13914/80
NauseaGastrointestinal disorders20/13914/80
DyspneaRespiratory, thoracic and mediastinal disorders20/13914/80
PyrexiaGeneral disorders24/1399/80
AnemiaBlood and lymphatic system disorders9/13913/80
NeutropeniaBlood and lymphatic system disorders0/13913/80
FatiqueGeneral disorders13/13912/80

Baseline characteristics

219 HLA-A2 positive patients with advanced NSCLC who progressed after sequential or concurrent chemotherapy and Immune Checkpoint Inhibitor (either primary or secondary resistance) were randomized. Safety analysis was done in overall population. Primary efficacy analysis was carried out from stratification factor in subgroup of patients with ICI secondary resistance (who had a disease progression after ICI second line \> or equal to 12 weeks)

Age, Categorical
Age, Categorical(Participants)OSE2101Docetaxel or PemetrexedTotal
All randomized patients with ICI primary and secondary resistance — <=18 years000
All randomized patients with ICI primary and secondary resistance — Between 18 and 65 years6945114
All randomized patients with ICI primary and secondary resistance — >=65 years7035105
Age, Continuous
Age, Continuous(years)OSE2101Docetaxel or PemetrexedTotal
All randomized patients with ICI primary and secondary resistance65.3 (41 to 86)63.6 (43 to 81)64.7 (41 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)OSE2101Docetaxel or PemetrexedTotal
All patients with ICI primary and secondary resistance — Female402464
All patients with ICI primary and secondary resistance — Male9956155
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OSE2101Docetaxel or PemetrexedTotal
All patients with ICI primary and secondary resistance — white12476200
All patients with ICI primary and secondary resistance — Black or African American426
All patients with ICI primary and secondary resistance — Asian202
Region of Enrollment
Region of Enrollment(participants)OSE2101Docetaxel or PemetrexedTotal
United States1457
Czechia011
Poland132
Italy301831
Israel834
France513146
Germany231
Spain331526
Hungary011
08

Study locations

78 sites
  • East Valley Hematology and Oncology medical Group
    Burbank, California 91505, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • BRCR Medical Center, Inc
    Boca Raton, Florida 33322, United States
  • Pontchartrain Cancer Center
    Covington, Louisiana 70433, United States
  • Meyer Cancer Center, Weill Cornell Medecine
    New York, New York 100001, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Robert W. Franz Cancer Center
    Portland, Oregon 97225, United States
  • Gesinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Millenium Oncology
    Houston, Texas 77090, United States
  • Nemocnice Jihlava, Onkologické oddelení
    Jihlava, 58633, Czechia
  • Všeobecná Fakultní nemocnice
    Praha, 12808, Czechia
  • Institut Saint Catherine
    Avignon, 84918, France
  • Hôpital Avicenne
    Bobigny, 93000, France
  • Institut Bergonié
    Bordeaux, 33076, France
  • CHGU Morvan - Brest
    Brest, 29200, France
  • Hôpital Louis Pradel
    Bron, 69500, France
  • Centre Hospitalier de Cholet
    Cholet, 49300, France
  • Hôpital intercommunal de Créteil
    Créteil, 94010, France
  • CHU Grenoble
    Grenoble, 38043, France
  • Clinique Victor Hugo
    Le Mans, 72000, France
  • Centre Hospitalier du Mans
    Le Mans, 72037, France
  • Hopital Albert Calmette
    Lille, 59000, France
  • Paoli-Calmettes Institute
    Marseille, 13273, France
  • CHU Montpellier
    Montpellier, 34295, France
  • Hôpital Emile Muller
    Mulhouse, 68100, France
  • Centre Catherine de Sienne
    Nantes, 44277, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • Hôpital Bichat - Claude-Bernard
    Paris, 75018, France
  • Hôpital Tenon
    Paris, 75970, France
  • Hôpital d'Instruction des Armées Bégin
    Saint Mandé, 94160, France
  • CHU de Strasbourg - Hôpital Civil
    Strasbourg, 67091, France
  • Hôpital Larrey - CHU de Toulouse
    Toulouse, 31059, France
  • Centre Hospitalier Régional Universitaire de Tours
    Tours, 37044, France
  • Centre Hospitalier Troyes
    Troyes, 10003, France
  • Institut Gustave Roussy (IGR)
    Villejuif, 94805, France
  • Krankenhaus Mehrheit - Kliniken der Stadt Köln - Lungenklinik
    Cologne, 51109, Germany
  • Klinik für Innere Medizin II Hospital Martha-Maria Halle-Dölau gGmbH
    Halle, 06120, Germany
  • Universitätsklinikum Tübingen Medizinische Klinik II
    Tubingen, 72076, Germany
  • Klinik für Innere Medizin II Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Magyar Honvedseg Egeszsegugyi Kozpont II szamu telephely
    Budapest, 1062, Hungary
  • Országos Korányi TBC és Pulmonológiai Intézet XI Tüdőbelosztály
    Budapest, 1121, Hungary
  • Országos Korányi TBC és Pulmonológiai Intézet XIV Tüdőbelosztály
    Budapest, 1121, Hungary
  • Semmelweis Egyetem Altalanos Orvostudományi Kar Pulmonologiai Klinika
    Budapest, 1125, Hungary
  • Csongrad Megyei Mellkasi Betegsegek Szakkorháza I Tüdőosztály
    Deszk, 6772, Hungary
  • Matrai Gyogyintézet
    Mátraháza, 3233, Hungary
  • Soroka University Medical Center
    Be'er Sheva, 84101, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Hadassah Campus Ein Kerem
    Jerusalem, 9087200, Israel
  • Meir Medical Center
    Kefar Saba, 44281, Israel
  • Rabin (Belinson) Medical Center
    Petah tikva, 4941492, Israel
  • IRCCS Oncologico Giovanni Paolo II
    Bari, 70124, Italy
  • Unità Operativa di Oncologia dell'Ospedale Vito Fazzi di Lecce, Piazza Muratore
    Lecce, 73100, Italy
  • Oncologia medica
    Legnano, 37045, Italy
  • Azienda USL 2 Lucca - Dipartimento Oncologico
    Lucca, 56124, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T)
    Meldola, 47014, Italy
  • U.O.C. Pneumologia a indirizzo oncologico, Presidio Ospedaliero Monaldi - Azienda Ospedaliera dei Colli - Via Leonardo Bianchi
    Napoli, 80131, Italy
  • Istituto Oncologico Veneto, IRCCS
    Padova, 35128, Italy
  • Ospedale di Perugia - Oncologia medica
    Perugia, 06126, Italy
  • U.O. Oncologia Ospedale Infermi
    Rimini, 47923, Italy
  • UOC di Oncologia Medica, Policlinico Universitario Campus Biomedico
    Roma, 00128, Italy
  • IRCCS Regina Elena National Cancer Institute
    Roma, 119, Italy
  • Policlinico Santa Maria alle Scotte
    Siena, 53100, Italy
  • Ospedale Civile Maggiore
    Verona, 37126, Italy
  • Klinika Onkologii i Radioterapii , Uniwersyteckie Centrum Kliniczne
    Gdańsk, 80-952, Poland
  • Przychodnia Lekarska "KOMED"
    Konin, 62-500, Poland
  • Mazowieckie Centrum Leczenia chorób Płuc i Gruźlicy
    Otwock, Poland
  • Wojewódzki Szpital Zespolony , Oddział Chemioterapii Nowotworów
    Toruń, 87-100, Poland
  • Hospital Universitari Quirón Dexeus
    Barcelona, 08028, Spain
  • Hospital Universitari Vall D'Hebron
    Barcelona, 08035, Spain
  • Hospital de Mataro
    Barcelona, 08304, Spain
  • Hospital Universitario Germans Trias i Pujol
    Barcelona, 08916, Spain
  • "Complejo Hospitalario Universitario A Coruna (CHUAC)"
    La Coruña, 15006, Spain
  • Hospital Universitario La Paz Servicio de Oncología Médica
    Madrid, 28046, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda Servicio de Oncología Médica Consultas externas, 2ª planta
    Madrid, 28220, Spain
  • Hospital de Mataro
    Mataró, 08304, Spain
  • Hospital Universitario Carlos Haya
    Málaga, 29010, Spain
  • Milton Keynes Hospital
    Milton Keynes, MK6 5LD, United Kingdom
09

References and documents

Publications

  • Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, Razaq M, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G; ATALANTE-1 study group. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol. 2023 Oct;34(10):920-933. doi: 10.1016/j.annonc.2023.07.006. Epub 2023 Sep 11. PubMed 37704166 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The supporting information as Study Protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR) may be shared with other researchers if OSE Immunotherapeutics agreed and after signature of a confidential agreement between the parties

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Jan 2021, 59 months.

Results were first posted in Feb 2024, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
Jan 13, 2016
StartActual
Feb 12, 2016
Primary completionActual
Jan 15, 2021
CompletionActual
Jan 15, 2021
Results first posted
Feb 2, 2024
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02654587
Lead sponsor
OSE Immunotherapeutics
Responsible party
Sponsor
First posted
Jan 13, 2016
Start date
Feb 12, 2016
Primary completion
Jan 15, 2021
Completion
Jan 15, 2021
Results posted
Feb 2, 2024
Last update
Feb 2, 2024

Study contacts

Dominique Costantini, Dr
study director · OSE Immunotherapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Multi-neo-epitope Vaccine OSE 2101

Start the discussion